Vir Biotechnology Secures the US FDA Fast Track Designation for VIR-5500 to Treat Prostate Cancer

Shots: The US FDA has granted Fast Track designation to VIR-5500 for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC) VIR-5500 is being evaluated in a P-I study across 6 dose-expansion cohorts, incl. monotx. in taxane-naïve, radioligand therapy-naïve & radioligand therapy-exposed mCRPC, & combinations with enzalutamide or docetaxel in early-line mCRPC, or darolutamide in…

ByRidhi Rastogi1 day ago

NEWS

Astellas Partners with Vir Biotechnology for VIR-5500 in ~$1.7B Deal

Shots: Astellas has partnered with Vir Biotechnology to advance VIR-5500, a PRO-XTEN dual-masked CD3 T-cell engager targeting PSMA, for the treatment of prostate cancer As per the deal, Astellas will fund 60% & Vir 40% of global development costs; Vir will continue the P-I trial until transition, after which Astellas will assume development. Also, Vir will…

ByRidhi RastogiFebruary 24, 2026

NEWS

Vir Biotechnology Licenses Tobevibart & Elebsiran Combination to Norgine in EU, Australia and New Zealand

Shots: Vir Biotechnology has granted Norgine Pharma, an affiliate of Norgine exclusive commercial rights to the combination of tobevibart & elebsiran for the treatment of chronic hepatitis delta (CHD) in EU, Australia & New Zealand As per the deal, Vir will receive ~$64.5M (€ 55M) as initial reimbursement payment & ~ $581.3M (€ 495M) in…

ByRidhi RastogiDecember 17, 2025

NEWS

Vir Biotechnology Reports First Patient Enrolment in P-III (ECLIPSE 2) Trial of Tobevibart + Elebsiran for Chronic Hepatitis Delta (CHD)

Shots: Vir Biotechnology has enrolled the first pts in P-III (ECLIPSE 2) trial assessing tobevibart + elebsiran in CHD pts who have not achieved undetectable HDV RNA despite prior bulevirtide treatment Trial will assess CHD pts treated with bulevirtide for ≥24wks., randomized to either switch to tobevibart + elebsiran or continue bulevirtide, with the 1EP…

ByRidhi RastogiAugust 1, 2025

TOP 20

Top 20 Biopharma Deal Terminations of 2024

Shots: In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…

ByPrince GiriMay 14, 2025

TOP 20

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

Shots: RNAi Therapeutic leverages the biological response of degrading (mRNA) before it gets translated into a protein. By using short double-stranded RNA in silencing a targeted disease-causing mutation, researchers are working steadfastly in multiple indications to expand RNAi therapeutic RNAi therapy comes to the rescue when targeting a specific protein gets difficult using a conventional…

ByPrince GiriApril 25, 2023

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named 'SARS-CoV-2'(severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named 'Coronavirus Disease 2019'(COVID-19). The outbreak of the respiratory disease was first detected in Wuhan…

BySenior EditorFebruary 28, 2020

Vir Biotechnology Secures the US FDA Fast Track Designation for VIR-5500 to Treat Prostate Cancer

Astellas Partners with Vir Biotechnology for VIR-5500 in ~$1.7B Deal

Vir Biotechnology Licenses Tobevibart & Elebsiran Combination to Norgine in EU, Australia and New Zealand

Vir Biotechnology Reports First Patient Enrolment in P-III (ECLIPSE 2) Trial of Tobevibart + Elebsiran for Chronic Hepatitis Delta (CHD)

Top 20 Biopharma Deal Terminations of 2024

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Contact US

FOLLOW US